The Saudi Arabia CDMO market was valued at USD 3.57 Billion in 2025 and is expected to grow at a CAGR of 6.00%, reaching USD 6.39 Billion by 2035. The market growth is driven by increasing global demand for MENA-based CDMO services and partnerships with international biopharma firms seeking regional access. The market is further impacted by the strong government backing under Vision 2030, prioritizing pharmaceutical self-sufficiency, and growing investment in local manufacturing infrastructure for APIs, biologics, and sterile injectables.
Base Year
Historical Period
Forecast Period
Saudi Arabia’s Vision 2030 initiative is accelerating CDMO growth by promoting pharmaceutical self-sufficiency and incentivizing local manufacturing partnerships.
The Riyadh–Makkah corridor is emerging as the central hub for sterile injectables and clinical-stage capabilities, attracting multinational collaborations and technology transfers.
Major market trends include a growing focus on oncology, metabolic, and infectious diseases is expanding demand for targeted CDMO services such as HPAPI production and phase-specific clinical trials.
Compound Annual Growth Rate
6%
Value in USD Billion
2026-2035
*this image is indicative*
The Saudi market is pivotal in supporting national healthcare resilience and Vision 2030 goals. Public Investment Fund (PIF), backed initiatives, international partnerships, and advanced manufacturing capabilities enable local production of sterile, biologics, mRNA vaccines, and ADCs. These efforts are critical for reducing import dependency, enhancing clinical trial readiness, and attracting global pharma investments, thereby fortifying Saudi Arabia's standing as a regional biotech manufacturing hub. The market is expected to grow at a CAGR of 6.00% during the forecast period of 2026-2035 and attain a market value of USD 6.39 Billion by 2035.
Emphasis on Promoting Local Pharmaceutical Manufacturing to Boost Market Growth
Strong government support and strategic localization goals are driving CDMO expansion in Saudi Arabia. The nation’s Vision 2030 initiative prioritizes local production of pharmaceuticals and biologics to reduce import dependency and improve health sector resilience. For instance, Vision 2030 outlines ambitions to increase the local pharmaceutical industry’s contribution to non-oil GDP and attract global partners to establish manufacturing within the Kingdom. These efforts are expected to boost CDMO demand, especially for high-value services like API synthesis and sterile injectables.
Major market trends include sovereign biotech investments and sterile facility expansions through global partnerships.
Sovereign Biotech Investments Strengthen Saudi CDMO Infrastructure
Strong government funding and Vision 2030 diversification goals are accelerating CDMO development. For instance, in December 2024, the Ministry of Investment (MISA) announced a SAR 1 billion (USD 266 million) partnership with Vertex to build a gene and cell therapy manufacturing facility in Riyadh, complete with viral vector and cell production lines and operator training. This initiative enhances local CDMO infrastructure, supports advanced therapy pipelines, and positions Saudi Arabia to compete internationally in biologics contract manufacturing.
Emphasis on Improving the Infrastructure to Boost the Saudi Arabia CDMO Market Demand
Driven by pandemic preparedness and regional export ambitions, Saudi Arabia has secured global CDMO know-how. For instance, in September 2023, Lifera and Resilience announced a JV to build a large-scale cGMP sterile injectables facility in Riyadh, including mRNA and monoclonal antibody production. This facility, set to produce over 125 million units annually, will create regulatory capacity, enable tech transfer, and reduce regional dependency on imports, boosting Saudi Arabia’s position as a rising CDMO hub.
Pharmaceutical and Biopharmaceutical Companies to Lead the Market Segmentation by End User
The pharmaceutical and biopharmaceutical companies are projected to hold the largest market share driven by PIF-backed investments, with a regional market CAGR of 5.7% during the forecast period. Lifera partnerships, and pipeline scale-ups, local and multinational biopharma sponsors are outsourcing advanced development and manufacturing needs. Focused collaborations in sterile, biologics, and vaccine domains are fueling segment growth, positioning contract services as central to the country’s biopharming ecosystem.
The Riyadh Makkah corridor remains the primary driver of Saudi Arabia’s CDMO infrastructure, supported by robust investments in advanced manufacturing and supply chain localization. Other regions, including Eastern Province and Qassim, are gradually expanding their capabilities through biotech clusters and downstream service integration. This regional diversification aligns with national efforts to reduce import dependency, enhance GMP compliance, and attract global pharmaceutical partnerships under Vision 2030, reinforcing Saudi Arabia’s emergence as a strategic CDMO destination in the Middle East.
The key features of the market report comprise grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Balsam Clinical Research, Dubai-based since 2018, entered Saudi CDMO through analytical and early-phase GMP lab services. It recently supported clinical manufacturing for monoclonal antibodies and cell therapies under Lifera partnerships. By focusing on sterile product analytics and scale-up, Balsam is building credibility in the Saudi biotech manufacturing ecosystem, complementing local and international CDMO operations.
Recipharm AB, founded in 1995 in Sweden, is active in Saudi Arabia via sterile injectable and oral solid development services. Since 2023, Recipharm has collaborated with Lifera and Arabio to support fill-finish packaging and serialization for vaccines under the national localization strategy. Its global compliance expertise and flexible manufacturing capabilities strengthen Saudi Arabia's CDMO capacity.
Boehringer Ingelheim, established in Germany in 1885, is expanding its BioXcellence™ CDMO presence in Saudi via advisory roles and tech transfer. Selected as a knowledge partner for upstream/downstream biologics production with Lifera, BI supports module design and regulatory readiness, accelerating the kingdom's local biomanufacturing readiness. Its global platforms anchor Saudi Arabia’s entry into advanced biologics CDMO.
Patheon Pharma Services (Thermo Fisher Scientific Inc.), based in the US since 1956, supports Saudi clinical and commercial CDMO needs through logistics, API supply, and process development. Recent partnership with Lifera-focused ventures enables small-molecule fill/finish and TGA/GCC-DR compliance advisory. Patheon’s involvement enhances Saudi Arabia's integrated CDMO infrastructure for drug developers.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Pfizer Inc., Al Hayat Pharmaceuticals, Lonza Group, WuXi AppTec, Fareva SA, FUJIFILM Diosynth Biotechnologies, Nipro Pharma Corporation, B. Braun SE, and WuXi Biologics.
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Service Type
Market Breakup by Therapeutic Area
Market Breakup by End User
Market Breakup by Region
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Service Type |
|
| Breakup by Therapeutic Area |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share